Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Cancer Res. 2015 Dec 17;76(1):117–126. doi: 10.1158/0008-5472.CAN-15-0694

Fig. 4. The selective TAK1 inhibitor 5z-7-oxozeaenol inhibits viability and TAK1 signaling of human primary keratinocytes (HEKa).

Fig. 4

(A) HEKa were treated with increasing concentrations of 5z-7-oxozeaenol for 72 h and cell viability was measured using MTT (3 experiments, n = 18). Data represent the mean ± SEM. (B) HEKa were treated with increasing concentrations of 5z-7-oxozeaenol or sorafenib for 1 h and Western blot analysis was performed using the indicated antibodies.